Larypront (Tablets) Instructions for Use
Marketing Authorization Holder
Hexalo Trading, Limited (Cyprus)
Manufactured By
October Pharma, S.A.E. (Egypt)
ATC Code
R02AA20 (Other antiseptics)
Active Substances
Lysozyme (DCF adopted for use in France)
Dequalinium chloride (Rec.INN registered by WHO)
Dosage Form
| Larypront | Lozenges 10 mg+250 mcg: 20 pcs. |
Dosage Form, Packaging, and Composition
| Lozenges | 1 lozenge |
| Lysozyme hydrochloride | 10 mg |
| Dequalinium chloride | 250 mcg |
10 pcs. – blister packs (2) – cardboard packs.
Clinical-Pharmacological Group
Topical antiseptic for use in ENT practice and dentistry
Pharmacotherapeutic Group
Antiseptic
Pharmacological Action
Lysozyme is a natural enzyme (mucopolysaccharidase) that forms a complex with viruses and prevents their penetration into cells, exerting an antiviral effect. It has an antimicrobial effect against gram-positive and some gram-negative bacteria by destroying the cell wall of microorganisms. Furthermore, lysozyme exerts anti-inflammatory, hemostatic, and mucolytic effects by blocking histamine, inactivating heparin, and breaking down mucopolysaccharides.
Dequalinium chloride is an antiseptic effective against gram-positive and gram-negative microorganisms, as well as fungi. By having the ability to reduce surface tension, it ensures the penetration of the active substances into the more deeply located areas of the mucous membrane.
Indications
Infectious and inflammatory diseases of the oral mucosa, pharynx, and larynx (gingivitis, periodontitis, stomatitis (including candidiasis, thrush), pharyngitis, laryngitis, tonsillitis); prevention of acute respiratory viral infections (ARVI); sore throat and hoarseness; before and after surgical interventions in the oral cavity and pharynx (dental operations, jaw surgery, maxillary sinus surgery, tonsil surgery).
ICD codes
| ICD-10 code | Indication |
| B37.0 | Candidal stomatitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04.0 | Acute laryngitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J31.2 | Chronic pharyngitis |
| J35.0 | Chronic tonsillitis |
| J37.0 | Chronic laryngitis |
| K05 | Gingivitis and periodontal diseases |
| K12 | Stomatitis and related lesions |
| R07.0 | Pain in throat |
| R49 | Voice disturbances |
| Z29.8 | Other specified prophylactic measures |
| Z51.4 | Preparatory procedures for subsequent treatment or examination, not elsewhere classified |
| ICD-11 code | Indication |
| 1F23.0 | Candidiasis of the lips or oral mucosa |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05.0 | Acute laryngitis |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA09.2 | Chronic pharyngitis |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| DA01.Z | Diseases of the oral mucosa, unspecified |
| DA0B.Z | Gingival diseases, unspecified |
| DA0C.Z | Periodontal diseases, unspecified |
| DA0Z | Diseases or disorders of the orofacial complex, unspecified |
| MA82.Z | Voice disturbances, unspecified |
| MD36.0 | Pain in throat |
| QB9A | Preparatory procedures for subsequent treatment |
| QC05.Z | Prophylactic measures, unspecified |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Dissolve one lozenge slowly in the mouth every two to three hours.
Adhere to a maximum of eight lozenges per 24-hour period.
For prevention of infectious and inflammatory conditions, reduce the frequency to one lozenge three times daily.
Use before and after surgical procedures in the oral cavity and pharynx as directed by a physician.
Initiate treatment at the first signs of throat discomfort, soreness, or hoarseness.
Continue treatment for several days after symptoms have resolved to ensure complete eradication of pathogens.
Do not exceed the recommended daily dose.
If symptoms persist beyond five days of self-treatment, discontinue use and consult a physician.
Adverse Reactions
In some cases, allergic reactions are possible.
Contraindications
Hypersensitivity to the components of the combination.
Use in Pregnancy and Lactation
Use during pregnancy and lactation is possible if indicated.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Belosalic, lotion solution for external use spray 100ml
No-spa pills 40mg, 64pcs
Belosalic, ointment, 30g
Noopept, pills 10mg, 50pcs
Ingavirin capsules 90mg, 10pcs
Kagocel pills 12mg, 30pcs
Mildronate capsules 500mg, 90pcs
Arbidol, capsules 100mg, 40pcs
Fenotropil pills 100mg, 60pcs 